Factors associated with mortality in transplant patients with invasive aspergillosis.

BACKGROUND Invasive aspergillosis (IA) is an important cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. The purpose of this study was to evaluate factors associated with mortality in transplant patients with IA. METHODS Transplant patients from 23 US centers were enrolled from March 2001 to October 2005 as part of the Transplant Associated Infection Surveillance Network. IA cases were identified prospectively in this cohort through March 2006, and data were collected. Factors associated with 12-week all-cause mortality were determined by logistic regression analysis and Cox proportional hazards regression. RESULTS Six-hundred forty-two cases of proven or probable IA were evaluated, of which 317 (49.4%) died by the study endpoint. All-cause mortality was greater in HSCT patients (239 [57.5%] of 415) than in SOT patients (78 [34.4%] of 227; P<.001). Independent poor prognostic factors in HSCT patients were neutropenia, renal insufficiency, hepatic insufficiency, early-onset IA, proven IA, and methylprednisolone use. In contrast, white race was associated with decreased risk of death. Among SOT patients, hepatic insufficiency, malnutrition, and central nervous system disease were poor prognostic indicators, whereas prednisone use was associated with decreased risk of death. Among HSCT or SOT patients who received antifungal therapy, use of an amphotericin B preparation as part of initial therapy was associated with increased risk of death. CONCLUSIONS There are multiple variables associated with survival in transplant patients with IA. Understanding these prognostic factors may assist in the development of treatment algorithms and clinical trials.

[1]  A. Glasmacher,et al.  Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 , 2010, The Journal of antimicrobial chemotherapy.

[2]  J. Sierra,et al.  Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single‐center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes , 2009, American journal of hematology/oncology.

[3]  Philippe Lutun,et al.  Factors associated with overall and attributable mortality in invasive aspergillosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Perfect,et al.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Y. Taur,et al.  Risk factors and attributable mortality of late aspergillosis after T‐cell depleted hematopoietic stem cell transplantation , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  J. Wingard,et al.  Changes in causes of death over time after treatment for invasive aspergillosis , 2008, Cancer.

[7]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Pagano,et al.  Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  N. Milman,et al.  Aspergillus infection in lung transplant patients: incidence and prognosis , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[10]  G. Rutherford,et al.  Estimating Severe Coccidioidomycosis in California , 2007, Emerging infectious diseases.

[11]  C. Heussel,et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Boeckh,et al.  Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Raoul Herbrecht,et al.  Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Fine,et al.  Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  C. Cordonnier,et al.  Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  G. Klintmalm,et al.  Combination of Voriconazole and Caspofungin as Primary Therapy for Invasive Aspergillosis in Solid Organ Transplant Recipients: A Prospective, Multicenter, Observational Study , 2006, Transplantation.

[17]  M. Boeckh,et al.  Combination antifungal therapy for invasive aspergillosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Russell E. Lewis,et al.  Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.

[19]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[20]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Latgé,et al.  Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  W. Leisenring,et al.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.

[23]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  G. Maschmeyer,et al.  Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. , 2007, Drugs.

[25]  L. Pagano,et al.  Design and Methods , 2022 .

[26]  J. Baddley,et al.  Antifungal combination therapy: clinical potential. , 2005, Drugs.

[27]  K. Wannemuehler,et al.  Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. , 2005, Medical mycology.

[28]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.